Canadian Neuromuscular Disease Registry Launches New Congenital Myasthenic Syndrome Registry

We’re delighted to announce that a new registry for patients with congenital myasthenic syndrome (CMS) has just been launched within the Canadian Neuromuscular Disease Registry (CNDR).  This new initiative is led by Dr. Hanns Lochmüller as an academic study as a part of Dr. Lochmüller’s CIHR foundation grant for CMS research, and supported by the NMD4C.

CMS are a diverse group of disorders that have an underlying defect in the transmission of signals from nerve cells to muscles. These disorders are characterized by muscle weakness that is worsened upon exertion[1]. The prevalence of CMS in populations under 18 years was measured to be between 2.8 and 14.8 per million children in a UK-based prevalence study[2]. This situates CMS as one of the rarer neuromuscular conditions, and there are over 30 different genes that may be involved.

By registering all patients across Canada, including those who have the clinical hallmarks of CMS but don’t yet have a genetic diagnosis, the aim of this registry is to improve access to diagnosis and treatment and develop a Canadian CMS cohort for future research. Individuals living with CMS can self-register directly with the CNDR or can register in-clinic if their local clinic is affiliated with the CNDR. Clinical centres that are already affiliated can activate the CMS module by going through a minor amendment with their REB – please contact Adrienna Dyck of the CNDR at to find out how to find out how. Since CMS is so rare, every new registration makes a difference!

The CNDR is a Canada-wide registry of people diagnosed with a neuromuscular disease, collecting important medical information from patients across the country to improve the understanding of neuromuscular disease and accelerate the development of new therapies. Currently, over 4500 neuromuscular patients have registered from across Canada. The new CMS registry is the latest addition to the CNDR’s current registries, which include Amyotrophic Lateral Sclerosis (ALS), Duchenne Muscular Dystrophy (DMD), Limb Girdle Muscular Dystrophy (LGMD), Myotonic Dystrophy (DM), Spinal Muscular Atrophy (SMA). The CNDR also collects information on other NMDs.

The network would like to give special recognition the CNDR’s Dr. Victoria Hodgkinson and Adrienna Dyck, and the Lochmüller Lab’s Dr. Rachel Thompson for their contributions to the CMS registry project, as well as members of the expert group who helped refine the dataset: Drs. Lawrence Korngut, Kathy Selby, Craig Campbell, Hugh McMillan, Nicolas Chrestian, and Dr. Hanns Lochmüller.

[1] NORD (National Organization for Rare Disorders). 2022. Congenital Myasthenic Syndromes – NORD (National Organization for Rare Disorders). [online] Available at: <> [Accessed 24 February 2022].

[2] Parr, J., Andrew, M., Finnis, M., Beeson, D., Vincent, A. and Jayawant, S., 2014. How common is childhood myasthenia? The UK incidence and prevalence of autoimmune and congenital myasthenia. Archives of Disease in Childhood, 99(6), pp.539-542.


Read next...

ImPORTND logo with text reading 'new module - skills for patient oriented research'

New Course ‘Skills for Patient Oriented Research’ Added to ImPORTND Training Platform

The third and final module of our patient-oriented research training platform, ImPORTND, is now available! ‘Skills for Patient-Oriented Research’ teaches specific skills to help with patient-oriented research (POR), including how to develop an effective patient engagement plan, share and listen to patient stories, and evaluate project engagement. 

MDC, NMD4C and CSCN fellowships competition is now open

Annual Neuromuscular Postdoctoral Research and Clinical Fellowships Funding Competition Now Open

Our 2024 annual funding competition to award postdoctoral fellowships in neuromuscular disease research, and clinical fellowship awards in neuromuscular medicine and electromyography is now open!


Curriculum Group Wraps up Inaugural Fellows’ Training Series

Our national neuromuscular lecture series launched last August 2022 has just wrapped up! The series consisted of a weekly (38 weeks) virtual Royal College CPD-accredited curriculum for neuromuscular fellows presented by subject-matter experts, developed by the curriculum working group together with the directors of fellowship programs across Canada.  

NMD4C and MDC together offer free training and support for research teams and patients to conduct patient oriented research

ImPORTND – Training for Research Teams and Patient and Family Partners to Conduct Patient-Oriented Research in Neuromuscular Diseases

We are partnering with Muscular Dystrophy Canada (MDC) to offer free training and support services for research teams and patients to empower all members of the research team to conduct research that is informed by, and most meaningful to individuals living with neuromuscular disorders. 

NMD4C awarded grant funding from CIHR-IMHA and funding from MDC for a period of 5 years.

Press Release | Neuromuscular Disease Network for Canada Awarded 5-Year Grant from CIHR-IMHA and Funding from MDC to Strengthen Canadian Neuromuscular Research and Care

The NMD4C has received a network grant from CIHR-IMHA and matched funding from MDC, providing funding of $400 000 per year for five years to strengthen the care, research and treatment of neuromuscular diseases for all Canadians.

Ottawa NMD conference poster

Important Deadlines for Ottawa NMD 2023

The Ottawa International Conference on Neuromuscular Disease and Biology (Ottawa NMD 2023) deadline for discounted early-bird registration and abstract submission is June 30th!